Sign up to save your podcasts
Or
Share Orthofix fires CEO and others with cause, Bausch+Lomb launches $1.4B offering
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Orthofix fires CEO and others with cause, Bausch+Lomb launches $1.4B offering
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, September 13, 2023.
Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast.
Procept BioRobotics this week won an FDA investigational device exemption (IDE) for its Aquablation prostate cancer therapy. Fast Five hosts Danielle Kirsh and Sean Whooley explain what the therapy is and what the company's plans are for the IDE.
The FDA has approved LimFlow's chronic limb-threatening ischemia (CLTI) treatment device. The approval enables the treatment to help those with CLTI with no other suitable endovascular or surgical treatment options available. Whooley dives into the device design in this episode.
Shockwave Medical is appointing a former Abbott Vascular executive as its chief medical officer. Find out who's taking on this role and what their career history is.
Bausch+Lomb launched a sizeable offering of senior secured notes worth $1.4 billion. Whooley explains the purpose behind the offering and provides more details into the company's latest acquisition.
Orthofix this week fired its CEO and two other executives with cause. After the announcement, analysts downgraded the company. The Fast Five hosts talk about the terminations, why the board made this decision and what analysts were thinking.
View all episodes
By MassDeviceWelcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, September 13, 2023.
Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast.
Procept BioRobotics this week won an FDA investigational device exemption (IDE) for its Aquablation prostate cancer therapy. Fast Five hosts Danielle Kirsh and Sean Whooley explain what the therapy is and what the company's plans are for the IDE.
The FDA has approved LimFlow's chronic limb-threatening ischemia (CLTI) treatment device. The approval enables the treatment to help those with CLTI with no other suitable endovascular or surgical treatment options available. Whooley dives into the device design in this episode.
Shockwave Medical is appointing a former Abbott Vascular executive as its chief medical officer. Find out who's taking on this role and what their career history is.
Bausch+Lomb launched a sizeable offering of senior secured notes worth $1.4 billion. Whooley explains the purpose behind the offering and provides more details into the company's latest acquisition.
Orthofix this week fired its CEO and two other executives with cause. After the announcement, analysts downgraded the company. The Fast Five hosts talk about the terminations, why the board made this decision and what analysts were thinking.